1
=
-
GE HealthCare Technologies Inc. Common Stock
As of May 21, 2026 at 10:37 UTC
Chart
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Market Statistics
Trading Metrics
How to Buy GEHC
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy GEHC
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesLaw firm Bragar Eagel & Squire is investigating GE HealthCare Technologies for potential securities law violations following the company's April 29, 2026 earnings announcement. GE HealthCare missed consensus EPS estimates ($0.99 vs. $1.05 expected) and reduced full-year 2026 guidance, citing a PDx supplier issue. The stock fell 13% ($9.01 per share) on the news. The firm is seeking investors who suffered losses to join the investigation.
Ventripoint Diagnostics has achieved multiple validation milestones in early 2026, including submitting its VMS+ 4.0 system to China's NMPA for expedited review, exhibiting at Europe's largest congenital cardiology conference, and establishing commercial partnerships for hospital deployment. The company is capitalizing on a shifting procurement environment where hospitals now demand economic proof alongside clinical accuracy for AI cardiac imaging solutions.
Law firm Bragar Eagel & Squire is investigating GE HealthCare Technologies for potential securities law violations following the company's April 29, 2026 earnings announcement. GE HealthCare missed Q1 2026 consensus EPS estimates ($0.99 vs. $1.05 expected) and reduced full-year guidance to $4.80-$5.00 from $4.95-$5.15, citing a PDx supplier issue. The stock declined 13% ($9.01 per share) on the news.
The global computer vision in healthcare market is projected to grow from $4.37 billion in 2026 to $33.4 billion by 2036, at a CAGR of 22.6%. Growth is driven by AI-integrated diagnostic systems, radiologist shortages, and precision medicine adoption. Software and medical imaging segments lead the market, while Asia-Pacific is expected to see the fastest regional growth.
The global healthcare analytics market is projected to grow from USD 56 billion in 2025 to USD 390 billion by 2034, with a CAGR of ~24%. Growth is driven by widespread EHR adoption, rising chronic disease prevalence, shift toward value-based care, AI/ML integration, and government digital health initiatives. North America leads with 44.36% market share, while Asia-Pacific emerges as a major growth engine.
